preview
Advertisement This month I have the pleasure of interviewing Caroline Baumal, who is professor of Ophthalmology at Tufts University in Boston, MA. Caroline…
Related Articles
Clinical Trial Update
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Gene Therapy for Wet Age-related Macular Degeneration
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Broader VEGF Pathway Inhibition for Wet AMD
VEGF-C and VEGF-D are innately involved in the neovascular etiology, so treating that component, in addition to traditional anti-VEGF-A treatment, may have the potential for…
Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni
Dr. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend.
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a…
Subspecialty News
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Polymeric Technologies for Retinal Drug Delivery
Polymeric technologies have the potential to revolutionize the intravitreal treatment approach for retinal diseases.
Artificial Intelligence and Augmented Intelligence in Ophthalmic Practice
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Improving Durability of Drugs in Wet AMD
Monthly or bimonthly anti-VEGF use poses significant time and cost burden due to the disease’s chronic nature and limited medication half-life. Further potential solutions to…